Transcode Therapeutics RNAZ
NASDAQ RNAZ
$2.87 -0.10 (-3.37%)
At close: Aug 21, 2026 · 4:00 PM EDT

Transcode Therapeutics (RNAZ) Goodwill (2025 - 2026)

Transcode Therapeutics' (RNAZ) quarterly Goodwill came in at $25.7 million in Q1 2026, little changed on a QoQ basis from $25.7 million in Q4 2025.

Transcode Therapeutics (RNAZ) Goodwill (2025 - 2026) Analysis & Trends

Transcode Therapeutics (RNAZ) has 2 years of Goodwill data on file, last reported at $25.7 million in Q1 2026.

  • Quarterly Goodwill changed N/A year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (changed N/A YoY) and the FY2025 annual result came in at $25.7 million, changed N/A from the prior year.
  • Goodwill was little changed at $25.7 million in Q1 2026, from $25.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $25.7 million in Q4 2025 to a low of $25.7 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Transcode Therapeutics 2.84 Mn 2.84 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 25.74 Mn
Dec 31, 2025 25.74 Mn